Copyright
Ciuoderis, K., Perez, L., Alvarez, C. et al.
Ciuoderis, K., Perez, L., Alvarez, C. et al. Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report. J Med Case Reports 17, 177 (2023). https://doi.org/10.1186/s13256-023-03904-2
Copyright © 2023 Ciuoderis, K., Perez, L., Alvarez, C. et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
A study published in the journal Vaccine evaluated the effects of a booster dose of BNT162b2 (Pfizer-BioNTech) vaccine on spike-binding antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
Files (203 downloads):
-
Ophthalmology
France
Les thrombi diffus sont tout de même dissous un an plus tard !? Même s'il peut persister une production de spike pendant plusieurs mois, ce n'est sûrement pas aux niveaux initiaux. Il est à noter que la production de spike semble varier énormément d'un lot de pfizer à l'autre, leur "mayonnaise vaccinale" n'étant pas homogène. Cela peut aller jusqu'à 250 fois plus de spike circulante qu'une infection covid. Dès lors, on comprend pourquoi certains supportent assez bien le vaccin et d'autres pas. Les phénomènes dysimmunitaires sont sans doute liés à la forte stimulation du système immunitaire associé à une vascularite diffuse. La pseudo polyarthrite rhizomélique et la maladie de Horton, d'origine vascularitique, sont des effets secondaires reconnus en France de la vaccination ARN.
__reactions__ -
-
In reply to SILVANA LOMAN MORALES
-
Ophthalmology
France
Je suis surpris que vous ayez eu une vaccination astra-zeneca, celle-ci ayant été interdite en France au bout de quelques mois, en raison de thromboses fréquentes chez les jeunes (perte d'un oeil chez une jeune infirmière, infarctus mésentérique fatal chez un jeune médecin en formation). Il a été rapporté sur ce site des cas de rhumatisme psoriasiques sévères post-vaccinaux, donc avec atteinte des interphalangiennes. Dans le cas de pseudo-polyarthrite rhizomélique que j'ai observé, la survenue des myalgies est apparue 6 mois après la vaccination pfizer, précédée de plusieurs mois d'altération isolée de l'état général. Le syndrome inflammatoire biologique était modéré : Vitesse de sédimentation normale, lente augmentation de la CRP qui n'a pas dépassé 18, élévation des plaquettes à 475 000. Il s'agissait d'une patiente âgée. Les douleurs étaient limitées aux cuisses, et une corticothérapie générale à faibles doses a entrainé une rapide disparition des signes et une amélioration de l'état général.
__reactions__ -
In reply to
-
Ophthalmology
France
J'ai observé une PPR dans les suites d'une 2° dose Pfizer, en l'absence de toute virose intercurrente covid et non covid. Altération de l'état général pendant trois mois, avec altération marquée de la fonction rénale qui avait été stable jusqu'à présent, puis lente augmentation de la CRP, et enfin, douleurs de PPR quatre mois après. Résolution du problème rhumatologique au bout d'un an de corticothérapie, fonction rénale toujours sévèrement compromise. La PPR post vaccin Pfizer et un effet secondaire reconnu du vaccin dans le dictionnaire Vidal français. Toute infection virale peut donner une PPR ou un Horton, en particulier la grippe et le covid. sachant que la vaccination pfizer peut parfois donner des doses de spike jusqu'à 250 fois supérieures à une infection covid, il ne faut pas s'étonner de voir, entre autres, des complications rhumatismales.
__reactions__
Major Drug Shortages Not Likely After Tornado Damages Pfizer Plant, FDA Says
MONDAY, July 24, 2023 (HealthDay News) -- Tornado damage to a Pfizer drug-making plant in North Carolina is unlikely to trigger drug shortages across the country, the U.S. Food and Drug Administration says.
"We do not expect there to be any immediate significant impacts on supply, given the products are currently at hospitals and in the distribution system," FDA Commissioner Robert Califf, M.D., said in an agency news release posted Friday. "Our initial analysis has identified less than 10 drugs for which Pfizer's North Carolina plant is the sole source for the U.S. market; however, a number of these are specific formulations for which there should be substitutes or for which many weeks' worth of stock should be available in Pfizer's other warehouses."
Meanwhile, Pfizer officials said the company is working to repair the damage and mitigate any shortage of drugs made at the facility.
"Clearly nature is strong. So, too, is ingenuity and the human spirit. A great deal of work needs to be done, but I assure everyone, most importantly the people of the Rocky Mount community, that we will put Pfizer's full power behind this effort," Pfizer Chairman and CEO Albert Bourla, M.D., said in a company statement. "We will work in lockstep with our partners and local authorities to restore and rebuild the site and the community."
The FDA said it cannot release any information about the specific drugs made or stored at the plant because of disclosure laws.
The Pfizer plant is closed as the damage is assessed. Most of the damage was caused to the warehouse, which stores raw materials, packaging supplies, and finished medicines, the company said. Pfizer is exploring alternative manufacturing locations, and there does not appear to be any major damage to the medicine production areas, the company added.
Copyright © 2020 HealthDay. All rights reserved.
Pfizer Warns of Shortage of Antibiotic Used to Fight Syphilis
FRIDAY, July 7, 2023 (HealthDay News) -- Infectious disease experts are warning that a shortage of a key antibiotic for treating syphilis could make it hard to fight the spread of the disease.
The United States already has a big problem with syphilis, with cases rising for more than 20 years. Cases increased nearly 75 percent between 2017 and 2021 alone, bringing the number to more than 176,000 in 2021, according to the U.S. Centers for Disease Control and Prevention. Meanwhile, drugmaker Pfizer recently announced the shortage of its Bicillin L-A, also known as penicillin G benzathine, which could continue into next year.
Reasons for scarcity of the long-acting injectable antibiotic include increasing demand because of the rising number of syphilis infections. The medication can also be used in place of amoxicillin to treat infections like strep throat as amoxicillin has also been scarce recently, The New York Times reported.
Among the concerns is congenital syphilis, which has a high fatality rate and can also lead to severe birth defects, The Times reported. Bicillin is the only recommended treatment for infected pregnant women.
Pfizer spokesman Steven Danehy told The Times it will likely take a year to increase production by 50 percent.
The CDC is recommending that doctors give preference for the medication to pregnant patients and infected or exposed infants. Others should be prescribed doxycycline for two to four weeks.
Copyright © 2020 HealthDay. All rights reserved.
2006 to 2019 Saw Significant Drop in Nicotine Dependence Prevalence
WEDNESDAY, June 28, 2023 (HealthDay News) -- Among U.S. adults with cigarette use and all subgroups aged 26 years and older, there were significant reductions in nicotine dependence prevalence from 2006 to 2019, according to a study published online June 23 in JAMA Network Open.
Beth Han, M.D., Ph.D., M.P.H., from the U.S. National Institutes of Health in Bethesda, Maryland, and colleagues examined whether and how nicotine dependence varies by year, age, psychiatric comorbidities, and sociodemographic characteristics among U.S. adults with cigarette use. Data were included from 152,354 U.S. community-dwelling individuals aged 18 years or older.
The researchers found that from 2006 to 2019, the adjusted prevalence of nicotine dependence decreased from 59.52 to 56.00 percent (average annual percentage change, −0.4 percent) and decreased in each age group, except for those aged 18 to 25 years who had stable prevalence. Among those with past-month cigarette smoking, the adjusted prevalence of nicotine dependence was 32, 18, and 6 percent lower for those aged 18 to 25, 26 to 34, and 35 to 49 years, respectively, compared with those aged 50 years and older. There was variation observed in the adjusted prevalence of nicotine dependence by age, major depressive episode and/or substance use disorder status, and sociodemographic characteristics.
"These results suggest the need to implement evidence-based tobacco cessation strategies that are specific to age and psychiatric comorbidities," the authors write.
One author disclosed ties to 3M, General Electric Company, and Pfizer.
Copyright © 2020 HealthDay. All rights reserved.
